PHASE-II EVALUATION OF MITOXANTRONE PLUS CISPLATINUM IN PATIENTS WITH ADVANCED BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY

被引：5
作者：
ATIBA, JO
GREEN, SJ
HYNES, HE
OSBORNE, CK
MILLER, TP
DAVIDNER, M
机构：
[1] UNIV CALIF IRVINE,COLL MED,IRVINE,CA 92717
[2] SW ONCOL GRP,CTR STAT,SEATTLE,WA
[3] WICHITA CCOP,WICHITA,KS
[4] UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX
[5] UNIV ARIZONA,ARIZONA CANC CTR,TUCSON,AZ 85724
[6] KANSAS CITY CLIN ONCOL PROGRAM,KANSAS CITY,MO
来源：
INVESTIGATIONAL NEW DRUGS | 1994年 / 12卷 / 02期
关键词：
CISPLATINUM; MITOXANTRONE; BREAST CANCER; PHASE I-II TRIAL;
D O I：
10.1007/BF00874442
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The Southwest Oncology Group studied the response rate and toxicity of mitoxantrone (7.5 or 10 mg/m(2) to 12.0 mg/m(2)) and cis-platinum (100 mg/m(2)) in 30 patients with advanced breast cancer as second-line therapy. There were 2 partial responses in 29 eligible patients. Toxicity was considerable, with 27 patients having grade 3 or 4 toxicity. Grade 3-4 toxicity included vomiting, thrombocytopenia, granulocytopenia, leukopenia and anemia. The combination of mitoxantrone plus cis-platinum has minimal activity as second-line therapy in metastatic breast cancer.
引用
收藏
页码：129 / 132
页数：4
相关论文
共 50 条
  • [21] A PHASE-II TRIAL OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN IN ADVANCED BREAST-CANCER
    KOCHUPILLAI, V
    GUPTA, P
    MISRA, A
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1992, 15 (05): : 388 - 391
  • [22] MITOMYCIN-C AND VP16 IN ADVANCED BREAST-CANCER - A PHASE-II STUDY
    SILVA, RR
    MATTIOLI, R
    BATTELLI, N
    PILONE, A
    ROSSINI, S
    DELPRETE, S
    BASCIONI, R
    MANOCCHI, P
    BATTELLI, T
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1993, 12 (01) : 49 - 52
  • [23] PHASE-II STUDY WITH MITOXANTRONE IN ADVANCED HEPATOCELLULAR-CARCINOMA
    BARONE, C
    ASTONE, A
    CASSANO, A
    VITETTA, GM
    NOVIELLO, MR
    MORICONI, L
    TORINO, F
    GRIECO, A
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1991, 10 (02) : 115 - 117
  • [24] PHASE-II STUDY OF EDATREXATE IN CHEMOTHERAPY-NAIVE PATIENTS WITH METASTATIC BREAST-CANCER
    SCHORNAGEL, JH
    VANDERVEGT, S
    VERWEIJ, J
    DEGRAEFF, A
    DULLEMONDWESTLAND, A
    VANDEIJK, WA
    HUININK, WWT
    [J]. ANNALS OF ONCOLOGY, 1992, 3 (07) : 549 - 552
  • [25] MITOXANTRONE, FLUOROURACIL PLUS L-LEUCOVORIN, AND VINORELBINE IN PRETREATED ADVANCED BREAST-CANCER
    COLLEONI, M
    NELLI, P
    GAION, F
    SGARBOSSA, G
    MANENTE, P
    [J]. ONCOLOGY, 1995, 52 (06) : 435 - 438
  • [26] MITOXANTRONE IN METASTATIC APUDOMAS - A PHASE-II STUDY OF THE EORTC GASTROINTESTINAL CANCER COOPERATIVE GROUP
    NEIJT, JP
    LACAVE, AJ
    SPLINTER, TAW
    TAAL, BG
    VEENHOF, CHN
    SAHMOUD, T
    LIPS, CJM
    [J]. BRITISH JOURNAL OF CANCER, 1995, 71 (01) : 106 - 108
  • [27] AN OVERVIEW OF PHASE-II STUDIES OF DOCETAXEL IN PATIENTS WITH METASTATIC BREAST-CANCER
    EISENHAUER, EA
    TRUDEAU, M
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A : S11 - S13
  • [28] PHASE-II TRIAL OF UFT ACTIVITY IN PRETREATED BREAST-CANCER PATIENTS
    DANIELS, M
    DIAZRUBIO, E
    GUILLEM, V
    MONTERO, JM
    GARCIACONDE, J
    ESTAPE, J
    MARTIN, M
    HERRANZ, C
    ORDONEZ, A
    GALAN, A
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1993, 23 (06) : 363 - 365
  • [29] VINCRISTINE WITH HIGH-DOSE ETOPOSIDE IN ADVANCED BREAST-CANCER - A PHASE-II TRIAL OF THE PIEDMONT-ONCOLOGY-ASSOCIATION
    THOMAS, GW
    MUSS, HB
    JACKSON, DV
    MCCULLOCH, J
    RAMSEUR, W
    MCFARLAND, J
    HOEN, H
    PAVY, M
    HEATH, R
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 35 (02) : 165 - 168
  • [30] PHASE-II STUDY OF DEOXYDOXORUBICIN IN PREVIOUSLY UNTREATED METASTATIC BREAST-CANCER
    MARTINO, S
    SAMAL, BA
    REDMAN, B
    FLAHERTY, L
    KRAUT, M
    SIMON, M
    VALDIVIESO, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1990, 17 (02) : 139 - 143
12345